Purchase Order 7571TE26P00075

The U.S. Food and Drug Administration (FDA) awarded a firm-fixed-price purchase order to Simulations Plus Inc., a for-profit software company specializing in pharmaceutical modeling and simulation. The contract, valued at $109,798.77, is for the purchase of 50 GastroPlus licenses, 30 IVIVCPlus module licenses, and 30 PBPK Plus licenses. The contract has no set-aside designation and is not associated with a larger contract vehicle. Simulations Plus has previously provided similar software...

The Environmental Protection Agency's Office of Research and Development awarded a $55,763.60 firm fixed-price purchase order to Simulations Plus Inc. for software licenses covering ADMET Predictor and GastroPlus, with an ultimate completion date of May 21, 2027. This award represents an option year exercise (OY2) under an existing contract structure, with no small business set-aside designation applied. The software will be delivered to the agency's location in Durham, North Carolina and...

This is a firm fixed-price purchase order awarded by the Department of Health and Human Services Food and Drug Administration to Simulations Plus Inc., a prime contractor that specializes in drug discovery and development simulation and modeling software. The $130,000 contract is for the extension and validation of Simulations Plus' GastroPlus ocular compartmental absorption and transit model. There is no set-aside designation for this contract. Simulations Plus has received over $5 million in...

The Food and Drug Administration awarded a purchase order to Anylogic North America, LLC for $119,895.92 to exercise option four providing AnyLogic software licenses and maintenance from August 17, 2026 through August 16, 2027. No set-aside applies. Performance occurs at Silver Spring, Maryland. The order covers simulation modeling software licensing and maintenance to support the Centers for Devices and Radiological Health's computational modeling and business process simulation requirements....

The Food and Drug Administration awarded a firm fixed-price purchase order to Certara UK LIMITED (doing business as Certara) on September 6, 2023, for SIMCYP software licenses with a ceiling value of $815,948. The contract will be performed in Great Britain, United Kingdom, and is scheduled for ultimate completion by September 20, 2028. No set-aside designation was applied to this award. Certara provides physiologically-based pharmacokinetic (PBPK) modeling software that simulates drug...

The Food and Drug Administration awarded a purchase order to Sentrysciences, Inc. valued at $55,000 on June 15, 2026 for an artificial intelligence and computational statistics platform to detect and classify protein aggregates in biosimilar drug products. Work is performed in Silver Spring, Maryland. The platform combines machine learning to generate morphological fingerprints of protein aggregates, differentiate particles by stress type and product, and employ neural network-based metric...

The Department of Health and Human Services, Food and Drug Administration awarded a fixed-price purchase order contract to Certara USA Inc., doing business as Tripos (De), for an annual Phoenix Quantum software subscription. The contract, with a potential value of $216,547.78, provides the FDA's Office of Clinical Pharmacology with the necessary modeling and simulation tools to analyze and verify sponsor submissions, including Investigational New Drug, New Drug, Biologics Licensing, and...

The Food and Drug Administration awarded a purchase order to Siemens Government Technologies Inc. for a gPROMS lyophilization modeling toolbox license on July 12, 2026, with a ceiling value of $35,449.44. The order covers one single-user license with a 12-month subscription, including nonlinear predictive control software optimized for high-performance computing to model time-dependent lyophilization cycles using first-principles equations. The platform incorporates an operational intelligence...

<p>The Food and Drug Administration issued a purchase order to Schrodinger LLC on June 27, 2023, for a Small Molecule Drug Discovery Suite license with a ceiling value of $248,024.00. Work is performed in Portland, Oregon. The firm fixed-price order extends through July 30, 2028.</p>

The U.S. Food and Drug Administration (FDA) awarded a Total Small Business set-aside purchase order to Certara USA Inc. for biopharmaceutical in vitro in vivo correlation and mechanistic modeling assessments software licenses. The contract, valued at $18,200, was awarded on September 19, 2022, with a completion date of September 20, 2023, and is structured as a firm fixed price purchase order. Performance of this work will occur in Calverton, Maryland. Certara USA Inc. is a leading biosimulation...